Market Currents
Celgene (CELG) -10.2% after EU regulators request more data about widening authorization of the...
-
Thursday, June 21, 2012, 8:22 AM ETCelgene (CELG) -10.2% after EU regulators request more data about widening authorization of the firm's multiple myeloma treatment Revlimid to treat newly diagnosed patients and as a maintenance therapy. Celgene is pulling the submission and will resubmit it with more data, and the firm is "re-evaluating" a similar FDA application. (PR)
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
